Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Mechanism of action of daratumumab

Niels van de Donk, MD, PhD from the University Medical Center, Amsterdam, Netherlands discusses the mechanism of action of daratumumab at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Daratumumab induces antibody-dependent cellular cytotoxicity (ACC), antibody-dependent cellular cell-mediated phagocytosis (ADCP) as well as complement-dependent cytotoxicity (CDC). Dr van de Donk further explains that daratumumab has been shown to eliminate regulatory T-cells, regulatory B-cells and myeloid-derived suppressor cells. The elimination of various immune suppressors may help the T-cell system to recover.